Fiinu (BANK), a fintech group and creator of the Plugin Overdraft®, announces that it has entered into an unsecured Sterling term loan facility agreement with Conister Bank Limited, the wholly owned banking subsidiary of Manx Financial Group PLC (AIM: MFX), for up to £2,000,000.
BANK said “We are pleased to have secured this flexible financing arrangement with Conister, which not only strengthens our capital position but also provides us with additional working capital support for our fast-growing FX brokerage in Poland. We expect the Loan to be converted in due course, which will see Manx Financial Group, through Conister Bank, become a strategic investor in Fiinu.”
Comment: BANK does its shareholders a favour with debt rather than equity. At the same time the deal with MFX underlines the merits of the relationship with Conister, and how keen one would presume MFX is on the arrangement.
Oberon (AQSE:OBE), the boutique wealth management and corporate broking group, is pleased to announce that Oberon Investments Limited has entered into a conditional asset purchase agreement with WH Ireland Limited for the acquisition of the business and certain assets of WH Ireland’s wealth management division for a cash consideration of £1 million, payable on completion.
Comment: As well as the ongoing people grab that OBE has been delivering, beefing up the head count / expertise, it can be seen the company is also keen to acquire businesses. The land grab as far as WH Ireland’s wealth management business is concerned looks to be a decent fit.
European Green Transition: From Exploration to Execution at The Investor Summit
Hydrogen Utopia International (HUI), a company pioneering plastic-to-hydrogen and waste-to-hydrogen solutions, announce that it has entered into a Memorandum of Understanding (“MOU”) with Shahab Ahmed and Mohamed Al Mir, from Muscat who have a strong track record for supporting international businesses navigating the Omani hydrogen market and decarbonising its industry.
Comment: The market has been nonchalant not only regarding the fact that HUI has the waste to energy technology, and in its chosen market in the Middle East, a hungry and rich market for its decarbonising offering.
Zenith Energy Ltd. (ZEN), the listed international energy production and development company, announced that its fully owned UK subsidiaries, Zenith Energy Africa Ltd, Zenith Overseas Assets Ltd and Compagnie du Désert Ltd, have filed their final submissions in respect of the ongoing international arbitration against the Republic of Tunisia before the International Centre for Settlement of Investment Disputes in Washington, an institution operating under the auspices of the World Bank. The Company also announced the appointment of TWCOG, a leading advisory firm with offices in London and Singapore. TWCOG was founded by Mr. Anthony Way, who has participated in more than sixty international disputes in the oil and gas industry.
Comment: ZEN was keen to underline some months back that its campaign against the Tunisian government, had hit a bump in the road, not the end of the line. This point is underlined by today’s news, and in particular the appointment of an expert in the dispute area.
Elixirr International (ELIX), an established, global award-winning, challenger consultancy, report its unaudited interim results for the six months ended 30 June 2025 (H1 25). Comparative unaudited results are presented for the six months ended 30 June 2024 (H1 24). 35% increase in revenue compared to H1 24, with revenue totalling £71.4m (H1 24: £53.0m) and Group record revenue achieved in five of the six months in the period. Organic revenue growth of 17% compared to H1 24. 42% increase in adjusted EBITDA compared to H1 24, totalling £21.5m (H1 24: £15.1m), with an adjusted EBITDA margin of 30.0% (H1 24: 28.5%).
Comment: A textbook positive growth company RNS, with all the right metrics moving in the right direction. The only missing ingredient perhaps is that few in the market will recognise the company name or what it does.
Rainbow Rare Earths (RBW) announced further successful results from the ongoing test work for the Phalaborwa project in South Africa. This unique project encompasses the recovery and separation of REE from phosphogypsum stacks, a waste product from phosphoric acid production, meaning that many of the costs, risks and long timescales associated with traditional mining projects are eliminated.
Comment: RBW was initially slow to join its peers in the REE space in terms of the great revival of 2025. But with news such as today the company appears to be well on its way, and makes a decent target for those who feel that other similar stocks have already moved up too far, too soon.
Cloudbreak Discovery (CDL), a London Stock Exchange Main Market listed company, announced the exercise of the option to acquire Phase 1 of Darlot West Gold Project that covers 60.6km2. Darlot West (Figure 1) is located only 10km southwest of the iconic Darlot Gold Mine in Western Australia with production of 2.8 million ounces of gold produced to date. The next phase of exploration has just been completed to further advance the project over the additional ~7km of greenstone belt strike, the host to where Cloudbreak recently discovered up to 28.62g/t Au from surface rock chip sampling, as announced on 21 August 2025.
Comment: The great revival at CDL should continue in the wake of the latest announcement, something which underlines the expansive mode the company is in.
Renalytix (RENX), a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, today announces its intention to raise a minimum of £4.0 million gross proceeds through a placing.
Comment: Anyone wondering why shares of RENX appeared rather heavy and did not rally as much as they perhaps should have in the wake of the recent collaboration news, now has their answer.
B90 Holdings (B90), an online marketing group for the global gaming industry, announced its unaudited interim results for the six months ended 30 June 2025. The Group delivered another period of strong operational and financial progress, reflecting the continued success of its transition to a lean, scalable, B2B-focused business model. The main KPI for the business is EBITDA which was more than 65% higher compared to the comparative prior period, at €0.3 million – driven by revenue growth, tight cost controls, and increased partner engagement. This success has continued into the second half of 2025. Revenues increased by 75% to €2.41 million (H1 2024: €1.38 million). EBITDA increased by 65% to €0.30 million (H1 2024: €0.18 million).
Comment: The stock market and gaming has not necessarily been a good mix, with something of a schism between the companies that do very well, and those that underperform. In the case of B90 it would appear that we are at a decent inflection point.
N4 Pharma (N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announced further details of its collaboration with world-renowned nonprofit R&D institute SRI on the targeted delivery of RNA into cells using Nuvec®. Following detailed additional analysis, the resulting data are now shaping a new scope of work focused on utilising Nuvec® for targeted treatments in oncology.
Comment: This does very much feel as though it is the time for the mini-biotechs, and N4P is illustrating the purple patch with this RNS. Up to 0.9p for the shares by the end of next month on a charting basis would not be out of the question.
EMV Capital (EMVC), the deep tech and life sciences VC investment group, announces that its wholly owned subsidiary, Moirai Acquisitions Limited (Bidco), has entered into an asset purchase agreement (APA) to acquire from Destiny Pharma Limited (Destiny Pharma), for a consideration of up to £2,475,000, certain assets relating to its XF drug platform, a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistance to its action and has advantages over traditional antibiotics.
Comment: Bacterial resistance to antibiotics is one of the biggest challenges in medicine, largely off the back of over prescription to hypochondriacs who want to pop a pill, and those who do not complete their pill popping doses. EMVC’s deal is therefore a canny one.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
